YDO1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Blockbuster Revenue GrowthSustained blockbuster sales and rapid patient adoption establish durable commercial scale, providing predictable product revenue to fund operations and pipeline investment. Large recurring prescription base reduces execution risk for U.S. commercialization and supports leverage of fixed infrastructure over time.
Very High Gross Margins / Strong Unit EconomicsExtremely high gross margins indicate attractive unit economics and pricing power, meaning incremental sales can drop to the bottom line once operating leverage and gross-to-net pressures normalize. This structural advantage supports long-term profitability potential as SG&A and R&D cadence stabilizes.
Diversified Pipeline And Milestone-driven CatalystsA broader pipeline and the ARO‑PNPLA3 siRNA entry materially diversify the company beyond a single product, creating multiple durable value drivers. Upcoming event-driven and histology readouts offer structural indication expansion opportunities that can extend lifetime revenue and reduce single-product concentration risk.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business still relies on financing or asset sales to sustain growth and fund trials. Even with improving trends, continuing cash burn constrains flexibility for sustained commercial investment or optionality for additional M&A without dilutive funding.
Rising Leverage Reduces Financial FlexibilityHigher debt relative to equity signals reduced balance-sheet optionality and increased fixed obligations. For a commercial-stage biotech still unprofitable, elevated leverage raises refinancing and covenant risks, limits the firm's ability to fund expensive trials or business development without costly or dilutive capital.
Material Gross-to-net Discounts And Royalty BurdenSustained mid-to-high 30% gross-to-net pressures and royalty obligations materially reduce realized revenue and margins versus gross sales. This structural drag lowers effective cash conversion on sales and compresses profit potential unless payor dynamics or contract structures improve long-term.
Madrigal Pharmaceuticals News
YDO1 FAQ
What was Madrigal’s price range in the past 12 months?
Currently, no data Available
What is Madrigal’s market cap?
Madrigal’s market cap is CHF10.02B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Aug 11, 2026 which is in 41 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on May 06, 2026. The company reported -$2.632 earnings per share for the quarter, beating the consensus estimate of -$3.426 by $0.794.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -2.23.
How many shares outstanding does Madrigal have?
Currently, no data Available
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$2.632 in its last earnings report, beating expectations of -$3.426. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in CH:YDO1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF548.09 (― Downside)
CHF548.09 (― Downside)
Insider Transactions
Sold Shares
Worth CHF353.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.32%
12-Months-Change
Fundamentals
Return on Equity
-50.15%
Trailing 12-Months
Asset Growth
23.15%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
YDO1 Company Deck
YDO1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all CH:YDO1 earnings summariesYDO1 Stock 12 Month Forecast
Average Price Target
$548.09
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Options Prices
Currently, No data available
---